Active Ingredient History

  • Now
Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.   Wikipedia

  • SMILES: Cc1ccc2cc(sc2c1)C(=O)NC3(CCCC3)C(=O)N[C@H](Cc4ccccc4)C(=O)NCC5CCN(CC6CCOCC6)CC5
  • Mol. Mass: 644.88
  • ALogP: 5.23
  • ChEMBL Molecule:
More Chemistry
6-methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide | ibodutant | men15596 | men 15596 | men-15596


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue